Use both names when taking notes
As of November 3, 2026, semaglutide has approved products including Ozempic and Wegovy, while tirzepatide has approved products including Mounjaro and Zepbound.
Source: FDA drug application records
An ingredient name says what the medicine contains. A product name identifies a particular finished drug. Here, ingredient name does not mean a generic version of a branded medicine. Write down both names when a drug is proposed. Also ask which form and which medical use the professional is discussing. An ingredient name does not tell you all about each drug that uses it.
Ask what the product is approved for
Wegovy has weight-management uses in its approved labeling, while Ozempic’s approved uses concern diabetes and specified related risks, as of November 3, 2026.
Source: FDA drug application records
Diabetes is a condition involving blood sugar. Weight care and diabetes care may overlap. Ask the person seeing you to name the purpose of the care. Keep that purpose with the drug name when you ask the plan to check coverage. The reason for prescribing matters to the next conversation as well as to the first one.
A pharmacy-made copy is not an approved generic
As of November 3, 2026, the United States has no generic semaglutide or tirzepatide product with approval allowing it to be sold.
Source: FDA drug application records
FDA identifies describing a compounded medicine as the same as an approved drug or as its generic version as false or misleading advertising.
Source: FDA on telehealth advertising
Generic is a drug approval term. It does not just mean cheaper. Compounded means mixed or changed to order. If a page calls that product a generic, ask what approval record it means. Return to the full product name rather than relying on similar branding or an image that resembles a familiar medicine.
National shortage status matters
The FDA’s supply policy, checked November 3, 2026, states that semaglutide and tirzepatide are absent from its drug shortage list.
Source: FDA supply and copy policies
Local stock can run out without a nationwide shortage being listed by FDA.
Source: FDA supply and copy policies
Ask for the actual national record if an explanation relies on shortage status. Keep that issue separate from the inconvenience of finding a prescription locally. The compounding page describes why the distinction matters when a preparation resembles an available approved medicine.
Ask who handles a confusing instruction
FDA has received reports of mistakes involving compounded injectable semaglutide, including events that required hospital care.
Source: FDA weight medicine concerns
Ask both the prescriber and pharmacist how to reach them about the drug you receive. Ask the people responsible for the prescription for clear information about the exact drug. Keep that information with their contact details.
Before comparing the bill, settle what the offer includes: an approved finished product, a compounded medicine, or something else. Leave any unclear answer open in your notes. Similar ingredient names do not remove the need to ask about the actual product being proposed.